Emergent BioSolutions receives honor from Lansing for continued investment

Emergent BioSolutions, Inc., a Rockville, Maryland-based biopharmaceutical company, is being honored by the Lansing Regional Chamber of Commerce for continued investment in global specialty pharmaceuticals in Lansing, Michigan.

Emergent BioSolutions spent between $125 million and $150 million in the region during the last decade. The company currently employs 450 of its more than 850 employees in the Lansing area. Emergent's Lansing facility produced the company's anthrax vaccine, the Lansing State Journal reports.

"We were established to make products to protect lives, around the world and specifically in Lansing. Every day we provide product that protects our country's soldiers and people all over the world," Adam Havey, the executive vice president and president of the BioDefense Division at Emergent, said, according to theLansing State Journal.

Emergent's Lansing site recently received the 2013 North American Maintenance Excellence Award by the Foundation for Industrial Maintenance Excellence. The award recognizes organizations excelling in maintenance processes that allow for operational excellence.

Havey said Emergent plants to continue expanding globally and locally in the Lansing area. The company has a goal of $300 million in revenue by 2015, the Lansing State Journal reports.

"We also want to introduce world health initiatives while continuing and growing our work with our military," Havey said, according to the Lansing State Journal.